Heidelberg Pharma to Unveil New Data at ASH 2026

Heidelberg Pharma AG is set to showcase significant clinical progress at the upcoming American Society of Hematology (ASH) Annual Meeting in December 2026. The company will present data for its Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101), targeting relapsed/refractory multiple myeloma. The Phase I/IIa study results, focusing on dose determination and preliminary antitumor activity, will be shared in an oral presentation by Professor Marc-Steffen Raab.

Additionally, the ADC HDP-102 will be discussed in a poster presentation. This candidate focuses on B-cell malignancies, demonstrating early signs of safety and biological activity. Despite discontinuing some studies, Heidelberg Pharma is seeking partnerships to advance its HDP-102 program.

These developments underscore the company's commitment to pioneering treatments using ATAC technology for complex cancers.